Lenders to the Nasdaq-listed jewelry maker reportedly have discoverd that 83 tons of gold used to borrow billions appear to be copper alloy bars.
The global nature of the Covid-19 crisis is clear in a filing in Delaware chancery court, as financing for flashy real estate deals has dried up.
My strategy for shares of the concert promoter is simple.
Shares of the shoe and apparel maker are reacting to reduced revenue guidance and word of government investigations into its accounting practices.
A lot of investing is just waiting until the market hates good companies.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.